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Hepatic lipogenesisMenin, encoded by the MEN1 gene, was initially identiﬁed as a tumor suppressor for endocrine neo-
plasia. Our previous report showed that Menin enhances PPARa transactivity preventing triglyc-
eride accumulation in the liver. Here, we further explore the role of Menin in liver steatosis.
Transient transfection assays demonstrate that Menin inhibits the transcriptional activity of nuclear
receptor liver X receptor a (LXRa). Accordingly, Menin overexpression results in reduced expression
of LXRa target genes, such as lipogenic enzymes including SREBP-1c, FASN and SCD-1.
Co-immunoprecipitation assays revealed physical interaction between Menin and LXRa.
Collectively, our data suggest that Menin acts as a novel corepressor of LXRa and functions as a neg-
ative regulator of hepatic lipogenesis.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Non-alcoholic fatty liver disease (NAFLD) or liver steatosis, an
important public health problem worldwide, is featured by triglyc-
eride (TG) accumulation in the hepatocytes [1]. In china, its preva-
lence has reached approximately 15% in adults [2]. However, the
molecular mechanism underlying the NAFLD progression is poorly
elucidated.
In general, the hepatic TG homeostasis is tightly controlled by
TG synthesis, b-oxidation and exported within very low-density
lipoprotein (VLDL)-TG [3]. The rate of hepatic lipogenesis depends
on multiple lipogenic enzymes, which are regulated by several
nuclear transcription factors including sterol regulatory element
binding protein 1c (SREBP-1c), carbohydrate responsive element
binding protein (ChREBP), Peroxisome proliferator-activated
receptor alpha (PPARalpha), liver X receptor a (LXRa), and farne-
soid X receptor (FXR) [4,5]. LXRa, a member of the nuclear receptor
superfamily, is known to induce the expression of SREBP-1c and
ChREBP [6]. As a result, activation of LXRa by agonistic compoundsup-regulate the expression of lipogenic enzymes, leading to TG
synthesis and liver steatosis [7].
Menin, the product of the MEN1 tumor suppressor gene, partic-
ipates in many cellular processes, including cell proliferation,
apoptosis and DNA damage [8,9]. Our previous study has found
that Menin expression was down-regulated in livers of obese mice,
suggesting that Menin might be involved in the regulation of hep-
atic TG homeostasis [10]. Indeed, adenovirus-mediated overex-
pression of menin successfully ameliorated the hepatic TG
accumulation in leptin receptor deﬁcient (db/db) mice [10]. At
the molecular level, we demonstrated that Menin interacted and
coactivated PPARa to enhance expression levels of genes related
to TG and fatty acid b-oxidation [10]. However, whether Menin
could regulate hepatic lipogenesis remain largely unexplored until
now.
2. Materials and methods
2.1. Cell culture and reagents
HEK293T and HepG2 cells were purchased from Cell Bank of
Type Culture Collection of Chinese Academy of Sciences (CAS,
Shanghai, China). Cells were cultured in Dulbecco modiﬁed
Eagle’s medium supplemented with 10% fetal calf serum (Gibco,
Shanghai, China), 100 IU/ml penicillin (Gibco) and 100 mg/ml
streptomycin (Gibco). Mouse primary hepatocytes were prepared
from C57BL/6 mice aged 8–10 weeks by collagenase perfusion
Fig. 1. Menin inhibits the transcriptional activity of LXRa. (A and B) LXRa
transcription activity is suppressed by Menin as shown in mouse SREBP-1c
promoter (200 ng) without (A) or with two LXRa binding sites mutations (B) in
HepG2 cells. Cells were transfected with Menin (50, 100, 200 ng) and LXRa (200 ng)
or empty vector (EV), and treated with T0901317 (T7, 1 lM) or vehicle control for
12 h. Each experiment was performed three times. Error bars represent S.E.M.
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T0901317 was purchased from Sigma–Aldrich (Sigma, St. Louis,
MO, USA). Cellular triglyceride contents were measured using
commercial kits (#K622, BioVision Inc., Milpitas, California, USA)
according to the manufacturer’s instructions.
2.2. Adenovirus, transient transfections and luciferase reporter assays
Adenovirus expressing murine Menin was obtained by
Invitrogen (Shanghai, China) with a full-length Menin complemen-
tary DNA (cDNA) coding sequence. Mouse SREBP-1c promoter pro-
moter constructs from 1500 to +150 were ampliﬁed from mouse
genomic cDNA and inserted into the pGL4.15vector (Promega,
Wisconsin, USA). Mutations were introduced into the SREBP-1c
promoter using the QuikChange II Site-Directed Mutagenesis Kit
(Toyobo, Shanghai, China) with primers (mutation sites under-
lined) 50-GTTGGGACGACAGTGAAGCCAGTAAAACCA-30, 50-AAGGC
GGACGAACGCTAGTAAAACCGG-30 and reverse complement pri-
mers. All the transient transfections were performed by
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s
instructions. For luciferase reporter assays, HepG2 cells were
seeded in 24-well plates and co-transfected with 200 ng
SREBP-1c promoter plasmids and Menin expression plasmids or
empty vectors (EV). Cells were harvested 36 h after transfection.
Luciferase activity was measured using the Dual Luciferase
Reporter Assay System (Promega, USA).
2.3. RNA extraction and real-time PCR analysis
Total RNAs were extracted from cells by TRIzol reagent
(Invitrogen, Shanghai, China), and reverse transcriptions were per-
formed by Takara RNA PCR kit (Takara, Dalian, China) following the
manufacturer’s instructions. In order to quantify the transcripts of
the interest genes, real-time PCR was performed using a SYBR
Green Premix Ex Taq (Takara) on ABI 7500 (ABI, CA, USA).
Expression of GAPDH was determined as an internal control. The
primer sequences are listed as below: Menin (Forward: 50-
TGTTCCCTCTGCGCTCTATC-30, Reverse: 50-GTGGGGATGACACGGTT
GAC-30); LXRa (Forward: 50-GCCTCAATGCCTGATGTTTC-30,
Reverse: 50-CTGCATCTTGAGGTTCTGTCTTC-30); SREBP-1c
(Forward: 50-TGACCCGGCTATTCCGTGA-30, Reverse: 50-CTGGGCTG
AGCAATACAGTTC-30); FASN (Forward: 50-GGAGGTGGTGATAGCC
GGTAT-30, Reverse: 50-TGGGTAATCCATAGAGCCCAG-30); SCD-1
(Forward: 50-TTCTTGCGATACACTCTGGTGC-30, Reverse: 50-CGGGA
TTGAATGTTCTTGTCGT-30); GAPDH (Forward: 50-TGGCCTTCCGTG
TTCCTAC-30, Reverse: 50-GAGTTGCTGTTGAAGTCGCA-30).
2.4. Western blot
Cells were lysed in radioimmunoprecipitation (RIPA) buffer
containing 50 mM Tris–HCl, 150 mM NaCl, 5 mM Mgcl2, 2 mM
EDTA, 1 mM NaF, 1% NP40 and 0.1% SDS. Protein extracts were
equally loaded onto SDS–PAGE electrophoresed, and transferred
to Nitrocellulose (NC) membranes (Amersham Bioscience,
Buckinghamshire, UK). After blocking with 5% nonfat milk in PBS,
the membranes were probed with antibodies followed by horse-
radish peroxidase-conjugated secondary antibodies. The signals
were detected by chemiluminescent substrate kit (Millipore
Corporation, Billerica, MA). The following antibodies were used:
anti-Menin (1:1000, Santa Cruz, California, USA), anti-SREBP-1
(1:500, Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA),
anti-LXRa (1:500, Santa Cruz, California, USA), anti-Flag
(1:10000, Sigma, USA), anti-HA (1:5000, Santa Cruz, California,
USA), anti-GAPDH (1:20000, Abcam, USA). The GAPDH protein con-
tent was employed as a loading control.2.5. Immunoprecipitation
HEK293T cells were transfected with Flag-Menin or HA-LXRa
for 48 h. Cells were harvested and lysed in lysis buffer (50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 0.5% Nonidet P40, and protease
inhibitor cocktail). Lysates were cleared by centrifugation and
supernatants were subjected to immunoprecipitation (IP) with
immobilized anti-Flag M2 beads (50 ll) overnight (Sigma). After
extensive washing, SDS loading buffer was added into the resin
and boiled. The samples were loaded and separated by SDS–
PAGE and immunoblotted with a HA antibody.
2.6. ChIP assays
To investigate the interaction of the indicated proteins with the
mouse SREBP-1c promoter, chromatin immunoprecipitation (ChIP)
assays was used. In brief, mouse primary hepatocytes were ﬁxed
with 1% formaldehyde to cross-link the proteins and DNA. DNA
was sheared to fragments at 200–1000 bp by several sonications.
The chromatin were incubated and precipitated with antibodies
against human LXRa (1:100), SRC-1 (1:100, Abcam), P300 (1:100,
Santa Cruz), or IgG (1:100, Santa Cruz).
2.7. Statistical analysis
All the cellular experiments were repeated for at least three
times. Values were shown as mean ± S.E.M. Statistical differences
Fig. 2. Menin overexpression inhibits expression levels of LXRa target genes. (A) Protein levels of Menin and LXRa in HepG2 cells transfected with adenoviruses containing
Menin (50MOI) or GFP as a negative control for 36 h. Cells were treated with T0901317 (T7, 1 lM) or vehicle control for 18 h. (B–D) mRNA levels of SREBP-1c (B), FASN (C) and
SCD-1 (D) were determined by real-time PCR in HepG2 cells overexpressing Menin or GFP. (E) Protein levels of Menin and LXRa in mouse primary hepatocytes (MPH)
transfected with adenoviruses containing Menin (100MOI) or GFP as a negative control for 36 h. (F–H) mRNA levels of SREBP-1c (F), FASN (G) and SCD-1 (H) were determined
by real-time PCR in MPH overexpressing Menin or GFP. Each experiment was performed four times. Error bars represent S.E.M.
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icance is displayed as ⁄ (P < 0.05), ⁄⁄ (P < 0.01) or ⁄⁄⁄ (P < 0.001).
3. Results
3.1. Menin inhibits the transcriptional activity of LXRa
In order to conﬁrm whether Menin has any effect on LXRa
transactivity, we performed transient transfection assays in
HepG2 cells using SREBP-1c promoter, which contains two LXRa
binding sites [11]. As shown in Fig. 1A, we found that Menin
dose-dependently decreased the reporter activity in the absence
or presence of T0901317 (T7), a synthetic LXRa agonist (Fig. 1A).
Meanwhile, LXRa expression was not suppressed by Menin over-
expression (data not shown). However, point mutations of both
LXRa binding sites greatly abolished the repressive roles of
Menin, indicating that this effect was dependent on LXRa
(Fig. 1B). Besides, similar results were also conﬁrmed in HEK293Tcells (data not shown). Moreover, the inhibitory roles of Menin
on the SREBP-1c promoter activity could be reversed by increasing
amounts of LXRa (Supplementary Fig. 1), further suggesting the
negative regulation of LXRa activity by Menin.
3.2. Menin inhibits expression levels of LXRa target genes
Next, adenoviruses containing Menin or GFP were generated
and infected into HepG2 cells (Fig. 2A). In agreement, Menin over-
expression signiﬁcantly suppressed endogenous SREBP-1c expres-
sion in the absence or presence of T0901317, while LXRa
expression remained unchanged (Fig. 2A and B). Besides, lipogenic
genes, such as fatty acid synthase (FASN), stearoyl-CoA desaturase
1 (SCD-1), were also down-regulated (Fig. 2C and D). Consistently,
we observed a similar effect in mouse primary hepatocytes (MPH)
(Fig. 2E–H). Indeed, ectopic expression of Menin decreased triglyc-
eride synthesis in MPH (Supplementary Fig. 2). Moreover, knock-
down of endogenous LXRa or SREBP-1 largely attenuated the
Fig. 3. Menin knock-down up-regulates LXRa target genes. (A) Protein levels of Menin and LXRa in HepG2 cells transfected with adenoviral shRNA targeting Menin (50MOI)
or negative controls (NC) for 36 h. Cells were treated with T0901317 (T7, 1 lM) or vehicle control for 18 h. (B–D) mRNA levels of SREBP-1c (B), FASN (C) and SCD-1 (D) were
determined by real-time PCR in HepG2 cells. (E) Protein levels of Menin and LXRa in MPH transfected with adenoviral shRNA targeting Menin (100MOI) or negative controls
(NC) for 36 h. (F–H) mRNA levels of SREBP-1c (F), FASN (G) and SCD-1 (H) were determined by real-time PCR in MPH. Each experiment was performed four times. Error bars
represent S.E.M.
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the negative regulation of lipogenic genes by Menin relies on
LXRa or SREBP-1.
On the other hand, knock down of Menin using adenoviral
shRNA led to an increase of SREBP-1c and lipogenic enzymes in
HepG2 and MPH (Fig. 3A–H). Therefore, our results suggest that
Menin could inhibit expression levels of LXRa target genes.
3.3. Menin interacts with LXRa and represses binding of coactivators
to LXRa
To investigate the molecular basis by which Menin represses
LXRa transcriptional activities, the interaction between Menin
and LXRa was examined. Immunoprecipitation assays in
HEK293T cells indicate that LXRa could be pull-downed by
Menin (Fig. 4A). Moreover, the interaction of endogenous Meninand LXRa was conﬁrmed in HepG2 cells and mouse liver nuclear
extracts (Fig. 4B and C). Given that LXRb also plays a critical role
in the regulation of hepatic lipogenesis (11), we also observed an
interaction between Menin and LXRb (Supplementary
Fig. 4A and B).
Since Menin could interact with LXRa to inhibit its transcrip-
tional activity, we speculate that Menin might repress binding of
coactivators to LXRa. As expected, the interactions between coac-
tivators (SRC-1 and P300) and LXRa was largely abolished by
Menin overexpression (Fig. 5A and Supplementary Fig. 5A). In
addition, our chromatin immunoprecipitation (ChIP) assays also
conﬁrmed that the recruitment of LXRa, SRC-1 and P300 to the
SREBP-1c promoter was signiﬁcantly increased after the treatment
of T0901317, which was impaired by Menin overexpression
(Fig. 5B and Supplementary Fig. 5B). In agreement with our previ-
ous observation that Menin was down-regulated in livers of obese
Fig. 4. The interaction of Menin and LXRa. (A) LXRa is pulled down by Menin by immunoprecipitation in HEK293T cells transfected with Flag–Menin and HA–LXRa. (B–D)
The interaction of endogenous Menin and LXRa. The protein lysates are extracted from HepG2 cells (B) and mouse liver (C, D), and immunoprecipitated using Menin, LXRa or
IgG antibodies and immunoblotted using LXRa or Menin antibody.
Fig. 5. Menin competes with coactivators for LXRa transactivation. (A) Immunoprecipitation assay of LXRa, SRC-1 and P300 showed that Menin overexpression competes
with SRC-1 and P300 bound to LXRa in HepG2 cells. Cells were transfected with adenoviruses containing Menin or GFP, and then immunoprecipitated using LXR antibody and
immunoblotted using SRC-1 and P300 antibodies. (B) ChIP assays in HepG2 transfected adenoviruses containing Menin or GFP. The immunoprecipitated DNA was ampliﬁed
with speciﬁc primers to analyze the binding activity of LXRa, SRC-1, P300 or IgG to the SREBP-1c promoter region. Cells were treated with T0901317 (T7, 1 lM) or vehicle
control for 1 h. (C) ChIP assays showing the binding activity of LXRa to the SREBP-1c promoter region in mice fed a normal diet (ND) or high-fat-diet (HFD) for 12 weeks.
(n = 5). (D) Representative protein levels of Menin in HFD mice transduced with adenovirus containing GFP or Menin for 10 days. (E–G) ChIP assays in livers from HFD mice
with Menin or GFP overexpression using SREBP-1c (E), ABCG1 (F) or ABCA1 (G) promoters. (n = 6). (H) Transient transfection assays of HepG2 cells cotransfected with SREBP-
1c promoter and expression constructs of Menin and LXRa or empty vector (EV). Cells were treated with TSA or EX527 as indicated. (I) ChIP assays using HDAC1, HDAC2,
HDAC3 and acetylated Histone H3 (Ac-H3) antibodies in MPH transfected adenoviruses containing Menin or GFP. Precipitated fragments were analyzed by real-time PCR.
Each experiment was performed four times. Error bars represent S.E.M.
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enhanced in the livers from mice fed a high-fat-diet (Fig. 5C),
which was dramatically reduced by adenovirus-mediated Menin
re-introduction (Fig. 5D and E). Besides, the enrichment of LXRa
on the promoter regions of its other down-stream target genes
(ABCG1 and ABCA1) were also suppressed by Menin overexpres-
sion (Fig. 5F and G).
It has been shown negative regulation of gene transcription by
Menin has been partly attributed to its interaction with histone
deacetylase (HDAC) proteins (12). Consistent with this, the HDAC
class I and class II inhibitor (Trichostatin A, TSA) but not the class
III (SirT1) inhibitor (EX527) abolished Menin-mediated repression
of LXRa transactivity (Fig. 5H). Moreover, our chromatinimmunoprecipitation assays revealed that Menin overexpression
recruited much more HDAC3, but not HDAC1 or HDAC2, to the
LXRa binding site of SREBP-1c promoter regions. In agreement,
acetylation of histone H3 was much lower in MPH overexpressing
Menin (Fig. 5I). Therefore, our results suggested that Menin might
repress LXRa transactivity via its recruitment of HDAC3.
4. Discussion
We have recently demonstrated that Menin could interact and
coactivate with PPARa to enhance TG b-oxidation. In the present
study, we found that over-expression of Menin signiﬁcantly
reduced LXRa transcriptional activities; whereas Menin
3084 P. Cheng et al. / FEBS Letters 589 (2015) 3079–3084knock-down signiﬁcantly increases LXRa target gene expression.
Therefore, our study suggests that Menin could act as a novel
co-repressor of LXRa in the liver. Interestingly, recent studies also
found that Menin could interact with FOXO1, in response to insulin
signaling [13]. Liver-speciﬁc hemizygous deletion of menin led to
increased expression of FOXO1 target genes, such as IGFBP-1,
PGC-1a, insulin receptor, and G6Pase [13]. Besides, Cao et al.
showed that Menin could regulate hepatic fatty acid uptake
through inhibition of CD36 [14]. Moreover, we found that knock-
down of endogenous SREBP-1 attenuated the inhibitory roles of
Menin (Supplementary Fig. 3C and D). As expected, the interaction
of endogenous Menin and SREBP-1 was observed in HepG2 cells
(Supplementary Fig. 6), suggesting the negative regulation of lipo-
genic genes by Menin may also rely on it regulation of SREBP-1
activity. Therefore, further studies are still needed to establish
the precise roles and mechanisms of Menin in the TG homeostasis.
Nuclear receptors including LXRa are usually bound to core-
pressors as a complex in the unliganded state [15]. Previous stud-
ies have shown that LXRa preferentially associates with
corepressors such as the nuclear receptor corepressor (NCoR) and
silent mediator of retinoic acid receptor and thyroid receptor
(SMRT) in the absence of cognate ligands [16]. Therefore, it would
be interesting to determine whether Menin could form a complex
with these corepressors. In addition, previous studies together
with ours suggest that menin is able to co-activate estrogen recep-
tor alpha (ERa) and PPARs mediated transcription [10,17,18].
However, previous studies have shown that Menin could also
repress transcriptional activity of some transcription factors. For
instance, Menin is a corepressor against JunD transcriptional activ-
ity via recruitment of histone deacetylases [19,20]. Besides, Menin
inhibits NF-jB-mediated transactivation through interaction and
recruitment of Sirt1 in hepatocellular carcinoma cells [12].
Therefore, together with these reports, we propose that Menin
could activate or repress expression of many target genes depend-
ing on its recruitment of cell-type speciﬁc tissue factors.
In summary, our data demonstrate that Menin could act as a
novel corepressor of LXRa via competing with coactivators such
as SRC-1 and P300, and recruitment of HDAC3. Understanding
the functional relationship of Menin and LXRa signaling might lead
to therapeutic therapies for NAFLD in the future.
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